A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated
Acta Pharmaceutica Sinica B
;
(6): 283-299, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-881137
ABSTRACT
AL3810, a molecular dual inhibitor of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), has earned the permission of phase II clinical trial for tumor treatment by China FDA. As a reversible ATP-competitive inhibitor, AL3810 targets ATP-binding site on intracellular region of VEGFR and FGFR, whereas, AL3810 lacking interplay with extracellular region of receptors rendered deficient blood-brain tumor barrier (BBTB) recognition, poor brain penetration and unsatisfactory anti-glioma efficacy. Integrin
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
Acta Pharmaceutica Sinica B
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS